In ovarian cancer, suppression of the glycosylation of ALCAM by kifunensine was shown to result in the reduction in membranous ALCAM and increase in the cytoplasmic fraction of ALCAM, which coincides with the decreased sensitivity to chemotherapy drugs, cisplatin for example, the work of [13]. This evidence concerns the gene ALCAM and ovarian carcinoma.